{"id":"clm_C3B4B1FC7983","entity":"regeneron-pharmaceuticals","predicate":"operating_income","value":"2,079,591,000 United States dollar","value_json":{"fy":2017,"accn":"0001532176-18-000013","form":"10-K","filed":"2018-02-08","concept":"us-gaap:OperatingIncomeLoss"},"valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 2,079,591,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_C3B4B1FC7983, https://asof.is/claim/clm_C3B4B1FC7983, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm.","url":"https://asof.is/claim/clm_C3B4B1FC7983","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B9BD4A691253","supersedes":["clm_1B4689E225C8"],"first_seen_at":"2026-11-08T17:08:51.481862+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000153217618000013/0001532176-18-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-08"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}